COMMUNIQUÉS West-GlobeNewswire

STERIS Announces Dividend of $0.63 per share
28/01/2026
DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
28/01/2026
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
L’Association canadienne pour l’équité en santé des femmes annonce une séance Conversations vitales sur les menstruations et la santé hormonale tout au long de la vie, présentée par Vichy Laboratoires
28/01/2026
Cycle menstruel, ménopause et plus encore – des expertes présenteront l’influence des hormones sur la santé des femmes à toutes les étapes de leur vie TORONTO, 28 janv. 2026 (GLOBE NEWSWIRE) -- L’Association canadienne [...]
Women’s Health Collective Canada Announces Vital Talks Event on Menstruation and Lifelong Hormonal Health, Presented by Vichy Laboratoires
28/01/2026
From menstrual cycles to menopause and beyond – experts explore how hormones shape health at every stage of life TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada is pleased to announce the [...]
GUERBET : Karim Boussebaa nommé Directeur général
28/01/2026
Karim Boussebaa nommé Directeur général de Guerbet Villepinte, le 28 janvier 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce la nomination [...]
NADP Foundation Announces 2026 Grants
28/01/2026
DALLAS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The National Association of Dental Plans (NADP) Foundation is pleased to announce the recipients of its 2026 grant awards, supporting innovative projects that improve access to [...]
Memorial Şişli Hospital Earns EARL “Theranostics Center of Excellence” for Nuclear Oncology Treatments
28/01/2026
ISTANBUL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Memorial Şişli Hospital’s (part of Memorial Hospitals Group ) Nuclear Medicine Department, Theranostics Unit has successfully completed the evaluation process under the [...]
Guerbet: Karim Boussebaa appointed Chief Executive Officer
28/01/2026
Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment [...]
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
28/01/2026
SAN FRANCISCO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s [...]
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
28/01/2026
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting – – Final data expected this [...]
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
28/01/2026
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees [...]
NetraMark Closes First Tranche of Private Placement
28/01/2026
TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) , a premier artificial intelligence (AI) company transforming clinical trials [...]
Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization
28/01/2026
Agricultural biologicals leader brings 15+ years of global R&D and product management experience from Syngenta to accelerate Genvor’s strategic partnerships and market expansion Woodland, CA, Jan. 28, 2026 (GLOBE [...]
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
28/01/2026
NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB [...]
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
28/01/2026
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a [...]
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
28/01/2026
Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical Data MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE [...]
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
28/01/2026
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report [...]
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
28/01/2026
WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet [...]
COUR Pharma Publishes Peer-Reviewed Data in Science Advances
28/01/2026
Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing ﬁrst-in-class, [...]

Pages